CEOs today seem to only be interested in the price of their own stock. They’re failing to invest in jobs and growth, says CNBC's Simon Hobbs.
Individuals can take advantage of the gains in emerging markets while making ethical investment choices. Financial advisors give their strategy tips.
While it's impossible to predict the future, there are some tech trends that are poised to take off in the coming year, experts say.
BlackBerry CEO John Chen says don't count them out yet. He's got a plan — and he's committed to being transparent about it. Here's his new strategy.
The unpopular individual mandate of Obamacare was unnecessary to the program's success, and it's going to hurt Democrats, said former DNC Chairman Howard Dean.
After a string of court cases and the advent of new technology, the music industry appears to be winning the battle against illegal downloads.
Billionaire Harold Simmons, one of the richest men in America and a major contributor to the Republican Party, has died at 82.
U.S. security services have intercepted computer shipments and hacked Microsoft's error reporting system, according to a Der Spiegel report.
Can do-gooder nonprofits learn from money-hungry hedge fund managers? Some have made the switch to find out.
This is a link to an NBC News story.
Cooper Tire & Rubber said on Monday it was terminating a proposed $2.5 billion sale to Apollo Tyres, saying the Indian tyre maker had failed to find financing for the transaction.
Signed contracts to buy existing homes rose slightly in November, breaking a five-month negative streak, according to the National Association of Realtors.
Long-time stock market bull Thomas Lee is looking for another double-digit gain in 2014.
Enrollment in the federal health insurance exchange surged in December, with almost half of the 975,000 signing up in the days before a Dec. 24 deadline. USA Today reports.
To prevent falling behind in capturing business in China, JPMorgan turned to a tactic used by rivals: hiring the children of China's ruling elite.
The White House is coming under pressure from some of its closest allies to name a CEO to run its health insurance marketplace.
Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.
Even with the yen at more than five-year lows, analysts expect a resurgent carry trade will keep Japan's currency on a downtrend well into 2014.
The SEC has asked life insurers to disclose the potential cost of forcibly winding down in-house insurance units known as "captives," The WSJ reports.
Some of the names on the move ahead of the open.